Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $185,145.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jazz Pharmaceuticals Stock Down 1.9 %

JAZZ opened at $120.23 on Thursday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $7.27 billion, a price-to-earnings ratio of 16.93, a PEG ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The firm’s 50-day simple moving average is $121.45 and its 200-day simple moving average is $113.89.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of JAZZ. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. GAMMA Investing LLC grew its holdings in Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 121 shares during the last quarter. Arizona State Retirement System increased its position in Jazz Pharmaceuticals by 0.8% in the 2nd quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock valued at $1,770,000 after acquiring an additional 130 shares in the last quarter. Coldstream Capital Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 7.7% in the third quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock worth $259,000 after acquiring an additional 165 shares during the last quarter. Finally, Itau Unibanco Holding S.A. lifted its position in shares of Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 172 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JAZZ. TD Cowen dropped their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Finally, Piper Sandler reissued an “overweight” rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.